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Abstract
Objective To determine the sensitivity and specificity of
hyperglycosylated hCG (hhCG) measurements for the diag-
nosis of clinical pregnancies in the IVF setting and how
soon post embryo transfer (ET) a pregnancy can be detected
using an ultrasensitive (hhCG) assay. To determine if a
single, early hhCG measurement can discriminate between
biochemical and clinical pregnancies.
Design A 4 center prospective blinded clinical trial was
performed with patients undergoing IVF-ET. Patients had
blood drawn and submitted for hhCG analysis on the day of
ET and at days 4, 6, 8, and 12 thereafter. First morning
urines were collected and submitted for hhCG analysis on
days 0, 4, 6, 8, 10 and 12.
Setting Fertility Centers
Outcome Measures Clinical pregnancies were defined as an
ultrasound study demonstrating a gestational sac and/or
heart beat at appropriate gestational ages.
Results Fifty-six of 58 enrolled patients completed the study.
There were 25 clinical and 6 biochemical pregnancies. For
blastocyst transfers, a single serum or urine hhCG measure-
ment identified pregnancies (both biochemical and clinical) at
6 days post ET with 100% sensitivity and specificity. There
were 6 biochemical pregnancies, all following blastocyst trans-
fers. All of these pregnancies were identified by lower values.
Keywords Pregnancy detection . IVF-ET . Biochemical
pregnancy
Introduction
For couples undergoing in vitro fertilization with embryo
transfer (IVF-ET), the interval between embryo transfer and
the first pregnancy test can be extremely stressful. One
patient describes in agonizing detail the “2WW” or “2 week
wait”. Her ordeal: waiting to know if the procedure has been
successful [1]. Even when the first pregnancy test reveals a
low level of hCG, further tests are usually necessary before a
definitive diagnosis of pregnancy can be made. Even after a
diagnosis of pregnancy there are several further weeks of
anxiety prior to the first ultrasound examination to deter-
mine if the pregnancy will fail or succeed.
Capsule A single serum hhCG measurement can determine a clinical
pregnance at 6 days post embryo transfer.
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In 1997 a unique molecule was isolated from the urine of
women with invasive trophoblastic disease [2]. Initially called
Invasive Trophoblast Antigen (ITA), the namewas changed to
hyperglycosylated human chorionic gonadotropin (hhCG)
when structural analysis revealed that ITA was actually a
hyperglycosylated isoform of human chorionic gonadotropin
(hCG) sharing an identical 92 amino acid alpha chain and a
145 amino acid beta chain. Both hCG and hhCG are glyco-
proteins. The 2 isoforms are differentiated by the extent and
complexity of sugar residues, with hhCG having more exten-
sive and more complex carbohydrate moieties.
Hyperglycosylated hCG is the primary hCG isoform
present during the initial 3 weeks of pregnancy [3–9]. A
monoclonal antibody, B152, was raised against hhCG, and
has >99 % specificity for hhCG relative to hCG [4, 8, 10].
Of note many antibodies raised to hCG have significant
cross reactivity with hhCG [11]. Early in pregnancy, hhCG
is the predominant isoform of hCG [12, 13].
Hyperglycosylated hCG is synthesized primarily by cyto-
trophoblasts, whereas hCG is produced by syncytiotropho-
blasts [12, 13]. The function of hhCG in early pregnancy
appears to be to facilitate the invasion of the embryo into the
uterine wall during implantation [13–15].
There are 3 potential advantages of measuring hhCG
rather than hCG for the diagnosis of pregnancy in the IVF-
ET setting. Because of the low cross reactivity of the B152
antibody with hCG, there is less interference from the iatro-
genic hCG administered during routine IVF to induce final
oocyte maturation. Since hhCG is presumably involved in
implantation by facilitating trophoblast invasion, hhCG
might be an excellent marker for implantation. In addition,
a previous study using urinary hhCG measurements, dem-
onstrated that hhCG rose 3 days sooner on average than
hCG levels in pregnancies using gestational surrogates. This
study also noted the ratio of hhCG to hCG could differen-
tiate between clinical and biochemical pregnancies [5].
We developed an ultrasensitive hhCG assay capable of mea-
suring hhCG at a lower limit of quantitation of 4.580 pg/ml in
both urine and serum. We conducted a prospective, blinded,
clinical trial of patients undergoing routine IVF in 4 centers in
order to determine the sensitivity and specificity of a single
hhCG measurement for the detection of pregnancy in the IVF
setting and establish how soon after ETan IVF pregnancy could
be detected. We also investigated whether hhCG levels could
discriminate between clinical and biochemical pregnancies.
Methods
Study design
This study was administered by the clinical research organi-
zation (CRO) Syteract in San Diego, California and approved
by the Western Institutional Review Board and the University
of California San Francisco Institutional Review Board.
Four sites participated in the study: The Center for Assis-
ted Reproduction in Bedford TX, HRC Fertility Center in
Los Angeles CA, the Advanced Reproductive Medicine
Center at University of Colorado in Denver CO, and the
University of California San Francisco Center for Repro-
ductive Medicine in San Francisco CA. Contributing centers
offered participation to all couples presenting for routine
IVF-ET. Couples using donor oocytes or embryos were
excluded from the study as were couples using frozen em-
bryos. Participating patients had blood drawn on the day of
ET, and at days 4, 6, 8, and 12 thereafter. A first morning
urine sample was obtained on days 0, 4, 6, 8, 10, and 12.
The samples were identified by case number and transported
to the laboratory where analysis was performed within
2 weeks of sample acquisition and data reported to the
CRO. The laboratory was blinded. Centers performed rou-
tine pregnancy testing and ultrasound confirmations accord-
ing to their usual protocols.
Each center reported the eventual results for each cycle to
the CRO. A clinical pregnancy was defined as a positive
pregnancy test using standard practices of the center and an
ultrasound demonstrating either a gestational sac or a gesta-
tional sac and heart beat at the appropriate gestational age. A
biochemical pregnancy was defined as a positive pregnancy
test with no gestational sac or heartbeat. A non-pregnancy
was defined as a negative pregnancy test. After all data had
been obtained, the code was broken and data analyzed. The
first patient was enrolled on 11/20/2010 and the final patient
was enrolled on 8/29/2011.
Ultrasensitive hhCG assay
A detailed description of this assay is beyond the scope of
this article and will be described elsewhere. Briefly, hhCG is
measured using an electrochemiluminescence (ECL) tech-
nique performed on a Mesoscale MSD Sector Imager 1250
(Meso Scale Discovery, Gaithersburg, Maryland). Assays
are performed in specially constructed 96 well microtiter
plates with integrated carbon-ink electrodes at the bottom of
each well. Capture antibodies are selectively attached to the
electrode surfaces and used in an antibody sandwich assay.
ECL-based assays employ compounds that emit light when
electrochemically oxidized or reduced under appropriate
chemical conditions. The hhCG assay employs two
affinity-purified monoclonal antibodies. The hhCG-specific
capture antibody B152 is pre-coated onto a specific elec-
trode of the multi-spot well. The signal is generated by the
hhCG and hCG reactive B207 antibody conjugated with the
MSD sulfo-Tag reagent.
The technical specifications achieved for this assay are an
analytic measurement range of 4.580–50,000 pg/ml and an
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inter-assay variation of 5.39 %, 3.47 %, 5.52 % and 7.68 %
for low, mid, mid-high and high level hhCG controls re-
spectively, and an intra-assay variability of 4.51 %, 3.57 %,
5.81 % and 6.51 % for the same controls, respectively. The
lower limit of detection is 0.512 pg/ml and the lower limit of
quantitation is 4.580 pg/ml.
Statistical methods
Determination of cut-off values was based on hhCG data
distributions with 100 % specificity. R was used as our
statistical package [16]. Other comparisons were performed
using Chi Square analyses.
A single individual, an M.D., with board certification in
Clinical Biochemical Genetics performed and analyzed all
test results. All tests were performed between 2 days and
2 weeks of specimen collection. No correction for missing
data was made. There were no adverse outcomes.
Results
There were 58 enrolled patients. Two patients withdrew
prior to completing the study leaving 56 completed cycles.
Not all women provided samples at all time points. The
mean patient age was 34.8 years with a range of 23–44 years.
There were 6 Asians, 4 African Americans, 6 Hispanics and
40 Caucasians. A single patient received 5,000 IU of hCG
for ovulation induction, another received 6,500 IU while all
others were given 10,000 IU. The mean weight of the
patients was 71.8 kg with a range of 46 kg–112 kg. Blasto-
cyst transfer was performed in 70 % of cycles and earlier
stage embryos transferred in 30 % of cases. The average
number of embryos transferred was 1.3 with a range of 1–2.
The overall clinical pregnancy rate was with 44 %. There
was no significant difference between the pregnancy rate
following blastocyst transfers (17 of 39, 44 %) versus earlier
stage embryo transfer (8 of 17, 47%). There were 12 singleton
and 13 twin pregnancies. There were no triplets or higher
order pregnancies. There were 6 biochemical pregnancies in
the series, all of them following blastocyst transfer.
Figure 1a and b represent the kinetics of the rise in hhCG
in serum for blastocyst and cleavage stage embryo transfers
respectively during the first 12 days following blastocyst
transfer. The Y axis is a log scale to accommodate the large
increases in hhCG we observed during early pregnancy.
On the day of transfer all but 2 patients had some meas-
ureable hhCG, presumably due to the cross-reactivity of the
B152 antibody with the exogenously administered hCG.
Ten thousand international units is equivalent to 1 g of
hCG. With a one percent cross-reactivity of the B152 anti-
body with hCG, and our assay sensitivity of 4.5 pg/ml, the
ability to detect residual hCG in these patients is well within
expectation even if >99.9 % of the hCG were already
eliminated. By day 6, serum and urine hhCG levels began
to rise in clinical pregnancies whereas there was a decline in
hhCG levels in non-pregnancies, presumably due to the
metabolism of injected hCG for ovulation induction.
Table 1 summarizes the performance of a single serum
or urine hhCG value in detecting clinical pregnancies fol-
lowing IVF-ET at various times following ET. For cycles
involving blastocyst transfer, a serum hhCG>75 pg/ml or a
urine hhCG>25 pg/ml has a sensitivity and specificity of
100 % in diagnosing pregnancy. Even as early as day 4,
a single serum hhCG value of>25 pg/ml had an 82 %
sensitivity and 87 % specificity.
Cycles involving cleavage stage embryo transfer are
more variable. There were 2 ultimately clinical pregnancies
Fig. 1 Kinetics of Serum hhCG levels following embryo transfer. a: Blastocyst transfer. Diamonds 0 non-pregnant. Rectangles 0 Failed
pregnancies. Circles 0 Clinical pregnancies. b Cleavage stage embryo transfer. Diamonds 0 non-pregnant. Circles 0 Clinical pregnancies
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with delayed hhCG rises until after 8 days. All other clinical
pregnancies were detected at days 6 and 8.
As noted above, all patients had a low level of detectable
hhCG on the day of transfer. In non-pregnancies, the level of
hhCG decreased steadily thereafter. In clinical and biochemical
pregnancies the hhCG levels did not fall during the initial 4 days
post-ET, indicating probable synthesis of hhCG by the pre-
implantation transferred embryos. By day 6, hhCG levels had
risen appreciably above day 0 levels. By day 12 hhCG levels
were approximately 100 fold higher than day zero levels.
Figure 2a and b demonstrate the kinetics of urine hhCG
values during the post ET period. Although the curves show
similar trends, the difference in urine hhCG values between
clincal and biochemical pregnancies is not nearly as pro-
nounced as for serum and urine hhCG values cannot dis-
criminate between them.
A commonly used calculation in monitoring early IVF-ET
pregnancies is the approximate doubling of hCG levels every
48 h in the period beginning approximately 12 days following
ET. We examined our data for the rate of increase for various
Table 1 Sensitivities and spe-
cificities for pregnancy (both
clinical and failed) for a single






Day 4: Serum hhCG>25 pg/ml All 9/24 18/25 72 % 72 %
Blastocyst 2/15 14/17 82 % 87 %
Cleavage Stage 7/9 4/8 50 % 22 %
Day 6: Serum hhCG>75 pg/ml All 0/19 19/21 90 % 100 %
Blastocyst 0/10 13/13 100 % 100 %
Cleavage stage 0/9 6/8 75 % 100 %
Day 8: Serum hhCG>175 pg/ml All 0/24 24/25 96 % 100 %
Blastocyst 0/15 17/17 100 % 100 %
Cleavage Stage 0/9 7/8 88 % 100 %
Day 12: Serum hhCG>175 pg/ml All 23/23 24/24 100 % 100 %
Day 4: Urine hhCG>15 pg/ml All 7/24 18/25 71 % 72 %
Blastocyst 2/15 11/17 65 % 87 %
Cleavage Stage 5/9 7/8 88 % 44 %
Day 6: Urine hhCG>25 pg/ml All 0/24 19/25 76 % 100 %
Blastocyst 0/15 17/17 100 % 100 %
Cleavage Stage 0/9 8/2 75 % 100 %
Day 8: Urine hhCG>25 pg/ml All 0/24 25/25 100 % 100 %
Day 10, Urine hhCG>200 pg/ml All 0/24 25/25 100 % 100 %
Day 12, Urine hhCG>200 pg/ml All 0/24 25/25 100 % 100 %
Fig. 2 Kinetics of urine hhCG levels following embryo transfer. a Blastocyst transfer. Triangles 0 non-pregnant. Diamonds 0 Biochemical
pregnancies. Circles 0 Clinical pregnancies. b Cleavage stage Embryo Transfer. Triangles: Non-pregnant. Circles: Clinical pregnancies
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48 h time periods for both singleton and twin pregnancies. For
the interval between day 4 and day 6, serum hhCG levels
increased on average 18 fold in singleton pregnancies and 13
fold in twin pregnancies. The increases were 4 fold for single-
tons and 5 fold for twins in the interval of day 6 to day 8.
Therefore the rate of rise of hhCG is not helpful in differen-
tiating singleton from twin pregnancies. Of note, between
days 6 and 8 hhCG rises much more steeply than the approx-
imate doubling of hCG in the second week following ET.
There were 6 failed pregnancies in our series, all follow-
ing blastocyst transfers. The hhCG levels are lower in bio-
chemical pregnancies than in clinical pregnancies (Figs. 1a
and 2a). Table 2 summarizes these data. A serum hhCG
level of <300 pg/ml was able to identify all of the failed
pregnancies at day 6 and a level of <6,000 pg/ml was able to
identify all of the biochemical pregnancies at day 12 (see
Table 2). A single clnical pregnancy was below the cut-off
value at day 6 and 2 pregnancies were below the cut-off
value at day 12. It is important to note that all these data
are for blastocyst transfers only. There were no cases of
biochemical pregnancies for cleavage stage embryo trans-
fers so no conclusions can be made. Urine hhCG levels
did not discriminate between clinical and biochemical
pregnancies.
Discussion
We performed a blinded prospective trial measuring serum
and urine hhCG levels in the 12 days following ET. We
determined that following a blastocyst transfer, a single hhCG
level measured in urine or serum is sufficient to differentiate
pregnant from non-pregnant patients with 100 % accuracy at
6 days post ET. Serum hhCG levels at 6 days and 12 days post
ET can distinguish biochemical versus clinical pregnancies
with a specificity of 100% and sensitivities of 92% and 88%,
at days 6 and 12 respectively. Because of the small numbers in
this study, these conclusions must be considered preliminary.
Further data will be collected in future series in order to
confirm these initial observations.
If used clinically, a patient who has an hhCG level above
300 pg/ml at 6 days following a blastocyst transfer can be
told that she probably will have an clinical pregnancy. A
patient with a level between 75 pg/ml and 300 pg/ml can be
told she likely has a biochemical pregnancy with a small
chance it will become a clinical pregnancy. A repeat hhCG
level could be drawn at 12 days post ET for these patients.
Any patient with an hhCG level below 75 pg/ml can be told
she is almost certainly not pregnant. Similarly, at 12 days
post blastocyst transfer, a level of>6,000 pg/ml is indicative
of a clinical pregnancy, levels between 175 pg/ml and
6,000 pg/ml indicate a probable biochemical pregnancy,
and levels below 175 pg/ml demonstrate a non-pregnancy.
It will be up to each individual clinician to interpret the
results for his or her patient.
Although a single urine hhCG value at 6 days post
blastocyst transfer is able to diagnose a pregnancy, urine
values cannot discriminate between biochemical and clinical
pregnancies. However, for patients who have difficulty trav-
eling for blood draws, urine hhCG measurement could be a
viable option for early pregnancy detection,
Although the data for cleavage stage embryo transfer is
not as decisive, hhCG can also be used in these cycles to
diagnose pregnancies (both biochemical and clinical) from
non-pregnancies in the IVF-ET setting. More data will be
necessary to determine the cut-off values to discriminate
between biochemical and clinical pregnancies following
transfer of cleavage stage embryos.
These data suggest that the primary cause of biochemical
pregnancies is deficient implantation as evidenced by low
hhCG levels at 6 days following blastocyst transfer. It can-
not be determined whether the lower levels of maternal
serum hhCG are the cause or the effect of this defective
implantation. It is intriguing to speculate that embryos that
synthesize less hhCG are less able to invade the uterine wall
for a successful implantation. If this is the case, it might be
possible to measure hhCG secreted into embryo culture
medium in order to select embryos with a higher likelihood
of establishing a clinical pregnancy. However, we cannot
rule out the possibility that the lower levels of hhCG
detected in chemical pregnancies are due to embryos secret-
ing the same amount of hhCG but that less material is
transferred to the maternal serum due to faulty implantation.
It should be noted that our sample size is small, contain-
ing only 6 biochemical pregnancies. It is certain that not all
biochemical pregnancies will eventually be detected by low
hhCG levels because there are multiple potential causes of
failed pregnancies other than implantation failure including
aneuploidy and other genetic abnormalities [17]. Our data
would suggest that the most common cause of biochemical
pregnancy is implantation failure. Since hhCG is produced
by the cytotrophoblasts of the embryo we assume that the
implantation failure is do to embryonic and not uterine
factors.
Future studies will be necessary to determine if hhCG
levels can be used to predict other adverse pregnancy out-
comes such as ectopic pregnancies and molar pregnancies.
Table 2 Discrimination between clinical and failed pregnancies using
serum hhCG for blastocyst transfers
Day post ET Clinical Chemical Sensitivity Specificity
6 day hhCG >0
300 pg/ml
12/13 0/6 100 % 92 %
12 day hhCG>0
6,000 pg/ml
14/16 0/6 100 % 88 %
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Elevated hhCG levels in the late first trimester (>09 week
gestation) and second trimester have been shown to be
associated with Down Syndrome pregnancies [18–23].
We developed an ultrasensitive hhCG assay for blood
and urine. This assay is capable of reliably detecting an
IVF-ET pregnancy as early as 6 days post ET in blood and
urine and also predict whether a pregnancy will be biochem-
ical or clinical . Although the performance of this testing is
best for blastocyst transfers, if one adds 2 days to accom-
modate for the additional time in tissue culture, pregnancy
detection is quite good for cleavage stage embryos. Wide-
spread use of this testing could significantly shorten the
period of anxiety sometimes referred to as the “two week
wait” for couples undergoing IVF-ET. The ability to dis-
criminate biochemical from clinical pregnancies will allevi-
ate much of the anxiety between the diagnosis of pregnancy
and confirmation by ultrasound.
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